A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis (AVVC)
Phase of Trial: Phase III
Latest Information Update: 12 Nov 2019
Price : $35 *
At a glance
- Drugs Ibrexafungerp (Primary)
- Indications Vulvovaginal candidiasis
- Focus Registrational; Therapeutic Use
- Acronyms Vanish 306
- Sponsors SCYNEXIS
- 12 Nov 2019 According to a SCYNEXIS media release, the company anticipates submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ibrexafungerp for the treatment of VVC in the second half of 2020.
- 07 Aug 2019 According to a SCYNEXIS media release, the company anticipates top-line data in the second quarter of 2020.
- 12 Jun 2019 Status changed from planning to recruiting.